Skip to content
Fresenius Medical Care Recent Study Validates Innovative Anemia Therapy Software Improves Clinical Outcomes for Hemodialysis Patients

Latest News

Fresenius Medical Care Recent Study Validates Innovative Anemia Therapy Software Improves Clinical Outcomes for Hemodialysis Patients

For Investors

The Conference Call on Q3 2024 financial results takes place on November 5, 2024
Healthcare innovation through technology: Augmented Reality, cloud-based data, and more >

Innovation

Healthcare innovation through technology: Augmented Reality, cloud-based data, and more
The Ogden Water Project: Community Conservation >

Sustainability

The Ogden Water Project: Community Conservation
The Impact of Antihypertensive Medications on Intradialytic Hypotension

Research

The Impact of Antihypertensive Medications on Intradialytic Hypotension

For Journalists

Fresenius Medical Care will publish its financial figures for the third quarter of 2024 on November 05, 2024

Healthcare Professionals

Products, therapies and services for Healthcare Professionals

Learn more

Patients & Families

Patients & Families

Learn more

WHO WE ARE

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment.

Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care.

~ 52 M

TREATMENTS

> 332,000

PATIENTS SERVED

~ 4,000

CLINICS

~ 40

PRODUCTION SITES

~ 120,000

EMPLOYEES